ClinicalTrials.gg
RecruitingNCT05773443JointEffort21Updated Mar 17, 2023

ANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB)

An observational study in Dementia, Lewy Body, sponsored by University of Bergen. Recruiting at 1 site in Norway. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-03-17.

Sponsored by University of Bergen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
50 Years to 85 Years
Sex
All
01

Study summary

The goal of the study is to develop predictive algorithms and digital biomarkers to capture disease fluctuations in (prodromal) dementia with lewybodies (DLB) patients and to improve treatment, diagnosis and prognosis of the study drug Ambroxol, used in the ANeED study. This project is an additional study to the ANeED study, registered at ClinicalTrials.gov under NCT04588285.

Read the detailed description

Currently, there is no approved treatment for DLB patients, despite the increasing prevalence of DLB. As disease symptoms fluctuate between days and within-day inpatient clinic visits do not adequately capture the fluctuation in disease symptoms. Therefore there is a need for continuous registration. Additionally as DLB caregivers report a high level of caregiver distress, we extended the study to include caregivers to collect data on caregiver distress.

For these reasons, a digital application was developed to report study medicine intake and side effects. Data collection from digital sensors (smartphone, smart watch, movement sensors, an EEG/EOG/ mood sensor and a bedside sleep monitor) register DLB symptoms continuously.

To be eligible to participate in ANeED Joint Effort 21, patients and their caregivers need to be included in the ANeED study. There will be no additional inpatient clinic visits in ANeED Joint Effort 21, as measurements in between the visits are performed in-home. These measurements include cognitive tests on the smartphone and health data gathered by a smartwatch. Additionally, 2 wearable movement sensors will measure activity and sleep, a bedside sleep monitor that registers sleep disturbances, as well as an EEG-EOG-mood sensor for a duration of one week.

02

Conditions studied

  • Dementia, Lewy Body

Keywords

  • dementia, lewy, wearable, sensor, digital, device, monitoring, actigraphy
03

In context

Lewy Body Disease

240 studies on the registry are indexed under Lewy Body Disease; 89 are open to participants now.

This study's planned enrollment of 100 is below the median of 280 across 83 observational studies indexed under Lewy Body Disease.

Browse Lewy Body Disease studies →

Lead sponsor

University of Bergen is the lead sponsor of 143 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants already included in ANeED drug trial with willingness to comply to the additional study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient is eligible when all inclusion criteria and none of the exclusion criteria are fullfilled in the ANeED study:

  1. Male or female.
  2. Age ≥ 50 and ≤ 85 years of age.
  3. Confirmed diagnosis of Dementia with Lewy Bodies (DLB) or Mild Cognitive Impairment in DLB (DLB-MCI).
  4. score>=15
  5. Able and willing to provide prior to any study related assessments and procedures at screening visit 1.
  6. Capable of complying with all study procedures.
  7. Willing to provide blood samples for genetic analyses of APOE and GBA.
  8. Willing and able to self-administer or administer by a caregiver oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
  9. Able to travel to the participating study site.
  10. A female participant is eligible to participate if she is of:

Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 consecutive months of spontaneous amenorrhea, at least 6 weeks post-surgical bilateral oophorectomy (with or without hysterectomy) or post tubal ligation. In questionable cases, menopausal status will be confirmed by demonstrating levels of follicle stimulating hormone (FSH) 25.8 - 134.8 IU/L and oestradiol \< 201 pmol/l at entry.

Women of child-bearing potential must use accepted methods (listed below), and must have a negative serum at screening visit 1 and urine pregnancy tests at subsequent visits if applicable. An additional pregnancy test will be performed, and results obtained, prior to administration of the first dose of ambroxol.

Exclusion criteria

Exclusion Criteria:

  1. Current treatment with anticoagulants (e.g. warfarin) that might preclude safe completion in the opinion of the Investigator.
  2. Current use of medicinal product or participation in another interventional clinical trial or who have done so within 30 days prior to the first dose in the current study.
  3. Exposure to more than three investigational medicinal products within 12 months prior to the first dose in the current study;
  4. Confirmed dysphagia that would preclude self-administration of ambroxol up to 6 tablets daily for the duration of day 1 to day 550/Month 18.
  5. Significant known lower spinal malformations or other spinal abnormalities that would preclude lumbar puncture.
  6. History of known sensitivity to the study medication, ambroxol or its (lactose monohydrate, granulated microcrystalline cellulose, copovidone and magnesium stearate) in the opinion of the investigator that contraindicates their participation.
  7. History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  8. History of illegal substance abuse, drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the study.
  9. Donation of blood (one unit or 350 ml) within three months prior to receiving the first dose of the study drug.
  10. Pregnant or breastfeeding; All participants of child bearing potential in the opinion of the Investigator that would preclude participation in the study and who do not agree to use double-barrier or abstinence while participating in the study and for two weeks following the last dose of study drug;
  11. Any or unstable psychiatric, medical or surgical condition that in the opinion of the PI or PI-delegated clinician may put the participant at risk when participating in the study or may influence the results of the study or affect the participant's ability to take part in the study, as determined by medical history, physical examinations, (ECG), or laboratory tests.

    Such conditions may include:

    1. Impaired renal function
    2. Moderate/Severe hepatic impairment
    3. A major cardiovascular event (e.g. myocardial infarction, acute coronary syndrome, decompensated congestive heart failure, pulmonary embolism, coronary revascularisation that occurred within 6 months prior to the screening visit.
    4. Major depression, delirium or psychosis not related to DLB.
    5. cancer or terminal illness.
  12. Planned major surgery or other major treatments during study period that will interfere with study-obligations.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ambroxol: Digital biomarkers

    Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550))

    Device: Digital biomarkers

  • Placebo: Digital biomarkers

    Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).

    Device: Digital biomarkers

  • Caregivers

    Primary family caregivers to participants

    Device: Digital biomarkers

Interventions

  • DeviceDigital biomarkers

    Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor

06

What researchers measure

Primary outcomes

  1. Digital biomarkers for diagnostic support and medication efficacy

    Time frame: All patient visits from start to 18 months (end of treatment).

07

Study locations

1 of 1 sites recruiting
  • Helse Fonna
    Haugesund, Rogaland 5528, Norway
    Recruiting
    • Arvid Rongve, PhD · Contactarvid.rongve@helse-fonna.no · 90548749
    • Dag Årsland, Professor · Principal investigator
    • Tormod Fladby, Professor · Principal investigator
    • Anne-Brita Knapskog, Professor · Principal investigator
    • Ragnhild Skogseth, Consultant · Principal investigator
    • John Fløvig, Associate professor · Principal investigator
    • Ole Kristian Grønli, Consultant · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2023; primary completion for Dec 2026, 45 months later.

Of 45 observational studies under Lewy Body Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 171. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 17, 2023
StartEst.
Mar 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05773443
Collaborators
Helse Fonna, Helse Stavanger HF, University Hospital, Akershus, Ullevaal University Hospital, Haraldsplass Deaconess Hospital, St. Olavs Hospital
Responsible party
Sponsor
First posted
Mar 17, 2023
Start date
Mar 2023 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 17, 2023

Study contacts

Arvid Rongve, PhD
Contact
arvid.rongve@uib.no
90548749
Jessica Hubbers, MSc
Contact
jessica.hubbers@helse-fonna.no
91692898
Arvid Rongve, PhD
principal investigator · University of Bergen / Helse Fonna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion